Journal of Cardiovascular Pharmacology最新文献_第2页

The therapeutic potential of hydrogen sulfide and its donors, a new discovery in vascular diseases. 硫化氢及其供体的治疗潜力，血管疾病的新发现。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-30 DOI: 10.1097/FJC.0000000000001714

Youzhen Pu, Wenlong Lin, Suyi Ren, Yuxu Gao, Guiming Wang

{"title":"The therapeutic potential of hydrogen sulfide and its donors, a new discovery in vascular diseases.","authors":"Youzhen Pu, Wenlong Lin, Suyi Ren, Yuxu Gao, Guiming Wang","doi":"10.1097/FJC.0000000000001714","DOIUrl":"10.1097/FJC.0000000000001714","url":null,"abstract":"Abstract: Hydrogen sulfide (H 2 S), an important gaseous signaling molecule, plays a critical role in maintaining vascular homeostasis. H 2 S participates in numerous biological functions, including redox regulation, interactions with other signaling molecules, and post-translational modifications of proteins through sulfhydration. Additionally, H 2 S influences key pathological processes such as inflammation, oxidative stress, and cell apoptosis. Dysregulation of endogenous H 2 S metabolism has been closely linked to the development of various vascular diseases, including aortic aneurysms, aortic dissection, atherosclerosis, and thrombotic conditions. Various endogenous and exogenous H 2 S donors have been developed, and these donors have demonstrated promising effects in preclinical models of vascular diseases such as atherosclerosis, pulmonary hypertension, and thrombosis by modulating oxidative stress, inflammatory pathways, and vascular remodeling. This review consolidates the current knowledge on the effects of H 2 S on vascular function and offers a comprehensive summary of recent advancements in the development and application of H 2 S donors in vascular disease research.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventing Contrast-Associated Acute Kidney Injury: Does the Choice of Statin Matter? 预防造影剂相关急性肾损伤：他汀类药物的选择重要吗？

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-29 DOI: 10.1097/FJC.0000000000001723

Anastasios Apostolos

引用次数: 0

Effect of HDAC4 regulation of β-catenin signaling pathway on cardiac injury in spontaneously hypertensive rats and its mechanism. hdac - 4调控β-catenin信号通路对自发性高血压大鼠心脏损伤的影响及其机制

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-29 DOI: 10.1097/FJC.0000000000001724

Ping Liu, Zhaohui Meng, Lei Zhang, Guangjuan Li, Hui Huang

{"title":"Effect of HDAC4 regulation of β-catenin signaling pathway on cardiac injury in spontaneously hypertensive rats and its mechanism.","authors":"Ping Liu, Zhaohui Meng, Lei Zhang, Guangjuan Li, Hui Huang","doi":"10.1097/FJC.0000000000001724","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001724","url":null,"abstract":"HDAC4 is highly expressed in patients with essential hypertension and is closely related to myocardial injury. Therefore, this study aims to explore the effects and mechanisms of HDAC4 on cardiac injury in spontaneously hypertensive rats, with the aim of providing new directions for the diagnosis and treatment of hypertensive myocardial disease.Compared with WKY group, the blood pressure, myocardial injury markers, myocardial cell apoptosis rate, cleaved-caaspase9 protein, TNF-α, HDAC4 mRNA, HDAC4 protein, IL-6, cleaved-caaspase3 protein, MDA, β-catenin protein, IL-1β, Wnt3a protein levels in SHR group significantly increased (P<0.05), while LVEF and SOD levels significantly decreased (P<0.05); interfering with HDAC4 expression can reduce the cardiomyocyte apoptosis rate, cleaved-caspase9 protein, TNF-α, HDAC4 mRNA, HDAC4 protein, IL-6, cleaved-caspase3 protein, MDA, β-catenin protein, IL-1β, and Wnt3a protein levels, and increase LVEF and SOD levels; Overexpression of HDAC4 has the opposite effect. HDAC4 may play a role in regulating cardiac injury in SHR rats by regulating β-catenin signaling pathway.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contractile Effects of Histamine in Mice Overexpressing H1-Histamine and H2-Histamine Receptors in the Atrium. 组胺对小鼠心房过表达h1 -组胺和h2 -组胺受体的收缩作用。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-29 DOI: 10.1097/FJC.0000000000001717

Thanh Hoai Pham, Lina Maria Rayo Abella, Igor Buchwalow, Uwe Kirchhefer, Katarina Hadova, Jan Klimas, Joachim Neumann, Ulrich Gergs

{"title":"Contractile Effects of Histamine in Mice Overexpressing H1-Histamine and H2-Histamine Receptors in the Atrium.","authors":"Thanh Hoai Pham, Lina Maria Rayo Abella, Igor Buchwalow, Uwe Kirchhefer, Katarina Hadova, Jan Klimas, Joachim Neumann, Ulrich Gergs","doi":"10.1097/FJC.0000000000001717","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001717","url":null,"abstract":"To identify the functional roles of human H1-histamine and H2-histamine receptors when they coexist in the heart, we crossbred mice that overexpressed human H1-histamine receptors only in the heart (H1-TG) with mice that overexpressed human H2-histamine receptors only in the heart (H2-TG) to obtain double transgenic mice (H1xH2-TG) and compared them with wild type (WT) mice. We measured the force of contraction (FOC) in isolated, electrically stimulated left atrial (LA) preparations and spontaneously beating right atrial (RA) preparations. We noted that when cumulatively applied (1 nM - 30 µM), histamine did not affect the force of contraction in the LA of WT mice. In H1xH2-TG mice, low concentrations (30 nM - 1 µM) of histamine increased the FOC in the LA, whereas higher concentrations (3 µM, 10 µM, 30 µM) of histamine reduced the FOC in the LA. Likewise, histamine in low concentrations (10 nM and higher) increased the beating rate in the RA, while higher concentrations of histamine (3 µM, 10 µM) reduced the beating rate in the RA. Dimaprit, an H2-histamine receptor agonist increased the force of contraction in the LA of H1xH2-TG mice but not in the LA of WT mice. 2-2-thiazol-ethan-amine (ThEA) an H1-histamine receptor agonist, increased the FOC in the LA of H1xH2-TG mice but not in the LA of WT mice. These data indicate that histamine, at least under our experimental conditions, at lower concentrations activates cardiac H2-histamine receptors, and at higher concentrations activated H1-histamine receptors.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ETS1-THBS1 Axis Regulates Macrophage Polarization and Exacerbates Myocardial Injury in Diabetic Cardiomyopathy. ETS1-THBS1轴调控巨噬细胞极化并加重糖尿病心肌病心肌损伤

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-20 DOI: 10.1097/FJC.0000000000001720

Xinbin Wang, Guligena Sawuer, Cheng Liang, Lu Lu, Gang Wu

{"title":"ETS1-THBS1 Axis Regulates Macrophage Polarization and Exacerbates Myocardial Injury in Diabetic Cardiomyopathy.","authors":"Xinbin Wang, Guligena Sawuer, Cheng Liang, Lu Lu, Gang Wu","doi":"10.1097/FJC.0000000000001720","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001720","url":null,"abstract":"Diabetic cardiomyopathy (DCM) is a major complication of diabetes marked by myocardial dysfunction, inflammation, and fibrosis. Immune cell infiltration and macrophage polarization are critical in DCM progression. This study examined the role of thrombospondin-1 (THBS1) and its upstream regulatory mechanism, particularly focusing on the transcription factor ETS1, in diabetic myocardial injury. Using an STZ-induced diabetic rat model, we observed significantly elevated THBS1 expression in the myocardium, accompanied by increased M1 macrophage infiltration and myocardial injury markers. Specific inhibition of THBS1 using shRNA lentiviral vectors significantly alleviated myocardial injury, reduced M1 macrophage polarization, and improved cardiac function. Additionally, ETS1 was identified as a transcriptional regulator of THBS1, and its knockdown resulted in decreased THBS1 expression, further reducing myocardial inflammation and fibrosis. In vitro, ETS1 knockdown in high glucose (HG)-treated H9C2 cells reduced THBS1 expression, cell injury, and fibrosis-related marker expression. These findings demonstrate that the ETS1-THBS1 axis contributes to diabetic myocardial injury by promoting M1 macrophage polarization and fibrosis. Targeting this axis may uncover a novel regimen for alleviating myocardial damage in diabetic patients.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TRPV4-dependent signaling pathways play essential regulatory roles in high salt-induced cardiac hypertrophy via autophagic alterations. trpv4依赖性信号通路通过自噬改变在高盐诱导的心脏肥厚中发挥重要的调节作用。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-19 DOI: 10.1097/FJC.0000000000001711

Yin Li, Rui Xu, Yuanteng Zhang, Kai Jiang, Tiecheng Zhong

{"title":"TRPV4-dependent signaling pathways play essential regulatory roles in high salt-induced cardiac hypertrophy via autophagic alterations.","authors":"Yin Li, Rui Xu, Yuanteng Zhang, Kai Jiang, Tiecheng Zhong","doi":"10.1097/FJC.0000000000001711","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001711","url":null,"abstract":"Cardiac hypertrophy, initially referred to as an adaptive response, would gradually transit to decompensated states over time, contributing to hypertension, and ultimately heart failure under salt overload. The cellular and molecular mechanisms driving salt-induced cardiac hypertrophy, as well as the signaling pathways responsible for this shift from compensation to decompensation, still remain insufficiently understood. Transient receptor potential vanilloid 4 (TRPV4) is ubiquitously expressed in cardiomyocytes, participating in cardiac remodeling and dysfunction. This study investigated TRPV4-relevant mechanisms in salt-induced cardiac hypertrophy. Knockdown of TRPV4 with cardiac gene transfer of Lv-shTRPV4 attenuated salt-induced cardiac hypertrophy, ROS generation, perivascular fibrosis and Akt & mTOR phosphorylation in adult rats. The in vitro results suggest that exposing cardiomyocytes to high-salt induced a concentration-dependent increase in autophagy, which was initially a rising phase and later followed by a declining phase. Salt-induced autophagic activity was enhanced by inhibiting Class I PI3-Kinase (PI3KC1) with LY294002 or Akt with AZD5363, but got undermined by AMPK inhibition with Compound C (CC) or SIRT1 inhibition with EX-527. Additionally, blockade of PI3KC1/Akt pathway significantly attenuated high salt-induced ROS generation and cardiac hypertrophy, whilst blockade of AMPK/SIRT1 pathway exacerbated high salt-induced cardiac hypertrophy via ROS accumulation. Thus, both PI3KC1 and AMPK signaling pathways participate in salt-induced cardiac hypertrophy via shared upstream component of TRPV4: lower salt triggers AMPK, scavenges ROS, preventing cardiac hypertrophy, whilst higher salt activates PI3KC1 with opposite effects. Our findings illuminate potential therapeutic effects of interfering TRP-related channels on high salt-induced hypertrophy and other mechanical stretch force-associated diseases.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bleomycin for Malignant Pericardial Effusion: A Systematic Review of Efficacy and Adverse Events. 博来霉素治疗恶性心包积液：疗效和不良事件的系统回顾。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-19 DOI: 10.1097/FJC.0000000000001713

Paulus Parholong Siahaan, Roy Bagus Kurniawan, Pandit Bagus Tri Saputra, Jannatin Nisa Arnindita, Cornelia Ghea Savitri, Luqman Hakim Andira, Estya Nadya Meitavany, Johanes Nugroho Eko Putranto, Firas Farisi Alkaff

{"title":"Bleomycin for Malignant Pericardial Effusion: A Systematic Review of Efficacy and Adverse Events.","authors":"Paulus Parholong Siahaan, Roy Bagus Kurniawan, Pandit Bagus Tri Saputra, Jannatin Nisa Arnindita, Cornelia Ghea Savitri, Luqman Hakim Andira, Estya Nadya Meitavany, Johanes Nugroho Eko Putranto, Firas Farisi Alkaff","doi":"10.1097/FJC.0000000000001713","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001713","url":null,"abstract":"Malignant pericardial effusion (MPE) is a progressive fluid accumulation in the pericardial space that can lead to pericardial tamponade. Despite the high recurrence rate associated with pericardiocentesis, it remains the mainstay therapy. Bleomycin has emerged as an intrapericardial sclerosing therapy that may reduce recurrence and improve patients' quality of life. This systematic review aimed to assess the efficacy and safety profile of Bleomycin instillation in patients with MPE. An exhaustive search was conducted in PubMed, Web of Science, Scopus, ProQuest, EBSCO, and ClinicalTrials.gov databases. Eligible studies included MPE patients as participants who were treated with intrapericardial Bleomycin, reporting the patients' outcomes and using English in the full text. Individual studies were assessed for quality using the Newcastle-Ottawa Scales for cohort studies and the Jadad Scale for trial studies. Eight studies were included in this systematic review involving 242 MPE patients treated with Bleomycin. Bleomycin demonstrated lower recurrence rates than other sclerosing agents, with only ≤5% of patients requiring repeated drainage due to recurrence. Bleomycin treatment resulted in 3.5 days less hospitalisation compared to doxycycline. Bleomycin is also safe to use, with reported less severe pain compared to other treatment agents for MPE, such as doxycycline and pericardiocentesis. Bleomycin may benefit patients by reducing recurrence rates and improving patients' quality of life. Moreover, it is safe and has low rates of adverse events following the instillation.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of short-term treatment with atorvastatin versus rosuvastatin for preventing contrast-associated acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a systematic review and meta-analysis. 阿托伐他汀与瑞舒伐他汀短期治疗对冠状动脉造影/经皮冠状动脉介入治疗患者预防造影剂相关急性肾损伤的比较：一项系统回顾和荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-14 DOI: 10.1097/FJC.0000000000001718

Mansour Bahardoust, Danyal Yarahmadi, Zahra Aghakhani, Mohammad Mahdi Kakoienejad, Mohammadsadra Shamohammadi, Babak Goodarzy, Ghazaleh Donyadideh, Shabnam Rashidi, Azin Ghaffari

{"title":"Comparison of short-term treatment with atorvastatin versus rosuvastatin for preventing contrast-associated acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a systematic review and meta-analysis.","authors":"Mansour Bahardoust, Danyal Yarahmadi, Zahra Aghakhani, Mohammad Mahdi Kakoienejad, Mohammadsadra Shamohammadi, Babak Goodarzy, Ghazaleh Donyadideh, Shabnam Rashidi, Azin Ghaffari","doi":"10.1097/FJC.0000000000001718","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001718","url":null,"abstract":"The effect of atorvastatin compared with rosuvastatin on the prevention of contrast-associated acute kidney injury (CA-AKI) after percutaneous coronary intervention (PCI) has been heterogeneous in different studies, which may be due to the small size of the initial studies. This systematic review and meta-analysis aimed to compare the effect of atorvastatin versus rosuvastatin on preventing CA-AKI in patients undergoing PCI. The databases PubMed, Embase, Google Scholar, Cochrane Library, and Web of Science were searched by two independent investigators from 2000 to 2024 to find articles that evaluated the effect of atorvastatin versus rosuvastatin on the prevention of CA-AKI in cardiac patients undergoing PCI. An absolute increase of serum creatinine (SCr) ≥0.3 mg/dl or an increase of ≥50% from baseline within 48 to 72 hours after contrast exposure was defined as CA-AKI. This systematic review and meta-analysis were conducted according to the PRISMA guidelines. Eight studies involving 3,998 Patients who underwent PCI were included. A pooled estimate of 8 studies showed that the overall incidence of CA-AKI after PCI in patients receiving statins, regardless of type, was 8.5 % (95% CI: 7.6, 9.3%). Subgroup analysis showed that the incidence of CA-AKI in patients receiving atorvastatin and rosuvastatin was 8.5% and 8.7%, respectively. The protective effect of atorvastatin on preventing CA-AKI in cardiac patients undergoing PCI was similar to that of rosuvastatin. Both atorvastatin and rosuvastatin similarly reduced the overall incidence of CA-AKI in patients undergoing PCI. The effects of atorvastatin and rosuvastatin on preventing CA-AKI after PCI were also similar.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Contemporary Landscape of Cardiac Tamponade: Insights from the CATEO Study and the Evolving Pharmacologic Spectrum. 心脏填塞的当代图景：来自CATEO研究和不断发展的药理学谱的见解。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-13 DOI: 10.1097/FJC.0000000000001719

Dor Lotan, Boaz Elad

引用次数: 0

Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis. 非他汀类降脂疗法对心血管风险增加的高胆固醇血症患者的比较疗效：一项最新的网络荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-05-13 DOI: 10.1097/FJC.0000000000001712

Heather Burnett, Allie Cichewicz, Harshul Natani, Debajyoti Bhowmik, Katharina Buesch, Kyle Fahrbach, Andreas Reichelt, Binod Neupane, Vicki Pierre, Ramandeep Jindal

{"title":"Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis.","authors":"Heather Burnett, Allie Cichewicz, Harshul Natani, Debajyoti Bhowmik, Katharina Buesch, Kyle Fahrbach, Andreas Reichelt, Binod Neupane, Vicki Pierre, Ramandeep Jindal","doi":"10.1097/FJC.0000000000001712","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001712","url":null,"abstract":"Abstract: Hypercholesterolemia is associated with atherosclerotic cardiovascular disease (ASCVD), a leading cause of morbidity and mortality. Non-statin lipid-lowering therapies (LLTs) such as ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs), bempedoic acid, and inclisiran have been recommended in clinical guidelines to treat patients with ASCVD and/or high cardiovascular (CV) risk having elevated low-density lipoprotein cholesterol (LDL-C) despite being treated with maximally tolerated doses (MTD) of statins. Our previously published network meta-analysis (NMA)1 was updated in this study to evaluate comparative efficacy of non-statin LLTs in reducing LDL-C among patients with ASCVD and/or high CV risk receiving MTD statins. The systematic literature review previously conducted to inform our NMA was updated through January 2023, wherein more recent clinical trials of non-statin LLTs (ORION-15, ORION-18, HUA TUO) and additional data on monthly dosing regimens for PCSK9 mAbs were included. The outcome of interest was percentage change in LDL-C at week 24. Random-effects Bayesian NMA was performed. Comparative efficacy was estimated as mean difference (MD) with 95% credible interval (CrI). A total of 20 trials were deemed relevant for the NMA. Consistent with the previous findings from our NMA, this study demonstrated that inclisiran provided superior efficacy in LDL-C lowering compared with ezetimibe and bempedoic acid (MD: -44.24 [95% CrI: -51.84, -36.70]). This NMA further reaffirmed that inclisiran provided comparable LDL-C reduction vs. alirocumab (MD: -1.93% [95% CrI: -8.56, 4.20]) and evolocumab (MD: 2.00% [95% CrI: -4.58, 8.60]) among patients with ASCVD and/or high CV risk on MTD statins.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0